Lymphocytic Cholangitis

Lymphocytic cholangitis is a chronic, progressive inflammatory hepatobiliary disease characterized by infiltration of the portal tracts and bile ducts with lymphocytes and plasma cells, leading to bile duct injury, cholestasis, and eventually fibrosis and cirrhosis. It is one of the most common causes of chronic hepatitis in cats, particularly in middle-aged to older cats, and is often associated with concurrent inflammatory bowel disease (IBD) and pancreatitis, forming the triaditis complex. The disease is typically insidious in onset, with clinical signs that may wax and wane, and can progress to end-stage liver failure if untreated. Histologically, it is distinguished from neutrophilic cholangitis by the predominance of mononuclear cells, and from hepatic lipidosis by the absence of marked hepatocellular vacuolation. The condition is also referred to as lymphocytic portal hepatitis or chronic cholangiohepatitis in some literature.

The exact etiology of lymphocytic cholangitis remains unclear, but it is believed to be immune-mediated, possibly triggered by an aberrant immune response to enteric antigens, bacterial products, or viral infections. In cats, a strong association with inflammatory bowel disease suggests a shared mucosal immune dysregulation, where increased intestinal permeability allows bacterial translocation to the liver via the portal circulation, stimulating a lymphocytic response. Some studies have implicated Helicobacter species, Bartonella henselae, and Toxoplasma gondii as potential infectious triggers, though definitive causation has not been established. Additionally, genetic predisposition may play a role, as certain breeds, such as the Persian and Siamese, appear to be overrepresented. Chronic antigenic stimulation from dietary components or environmental allergens may also contribute. The immune response is characterized by a Th1-dominant cytokine profile, with increased expression of interferon-gamma and tumor necrosis factor-alpha, leading to lymphocyte recruitment and bile duct damage.

Lymphocytic cholangitis is primarily a disease of cats, with a reported prevalence of 10-20% in cats with hepatobiliary disease. It is less commonly diagnosed in dogs, where similar histologic patterns may be seen in chronic hepatitis. In cats, the disease typically affects middle-aged to older animals, with a median age of 7-10 years. There is no strong sex predilection, though some studies suggest a slight female predominance. Breed predispositions have been reported in Persian, Siamese, and Himalayan cats, possibly due to genetic factors. The disease is more common in indoor cats, possibly due to increased exposure to dietary antigens or reduced immune tolerance. Geographic variation is not well-documented, but the condition is recognized worldwide. Concurrent diseases, particularly inflammatory bowel disease and pancreatitis, are present in up to 50-80% of affected cats, and the presence of triaditis is associated with more severe clinical signs and a poorer prognosis.

The pathophysiology of lymphocytic cholangitis involves a complex interplay between the immune system, the gut-liver axis, and the biliary epithelium. The initial trigger is likely an increase in intestinal permeability, allowing bacterial products and dietary antigens to reach the liver via the portal vein. These antigens are presented to T lymphocytes in the portal tracts, leading to activation and clonal expansion of CD4+ and CD8+ T cells. The activated lymphocytes produce pro-inflammatory cytokines, including interferon-gamma, tumor necrosis factor-alpha, and interleukin-2, which recruit additional inflammatory cells and activate hepatic stellate cells. The inflammatory infiltrate surrounds the bile ducts, causing damage to the biliary epithelium through direct cytotoxicity and apoptosis. This leads to impaired bile flow, cholestasis, and accumulation of toxic bile acids within hepatocytes, causing secondary hepatocellular injury. Chronic inflammation results in progressive fibrosis, with deposition of extracellular matrix proteins in the portal and periportal regions. Over time, this fibrosis can progress to cirrhosis, with nodular regeneration and loss of liver function. The disease is also associated with a systemic inflammatory response, contributing to anorexia, weight loss, and fever. The concurrent presence of inflammatory bowel disease and pancreatitis suggests a shared mucosal immune dysregulation, with the liver, gut, and pancreas all being targets of the same aberrant immune response.

Predisposing factors for lymphocytic cholangitis include genetic susceptibility, as certain breeds (Persian, Siamese, Himalayan) are overrepresented. Age is a significant factor, with middle-aged to older cats being most commonly affected. Concurrent inflammatory bowel disease is a major risk factor, as it increases intestinal permeability and bacterial translocation. Chronic pancreatitis is also commonly associated, and the presence of triaditis (inflammation of the liver, pancreas, and intestine) is a well-recognized clinical entity. Environmental factors, such as indoor housing and dietary changes, may contribute to immune dysregulation. Immunosuppressive conditions, such as feline leukemia virus (FeLV) or feline immunodeficiency virus (FIV) infection, may increase susceptibility, though their role is not fully established. Chronic use of certain drugs, such as glucocorticoids or non-steroidal anti-inflammatory drugs, may also predispose to immune-mediated liver disease. Obesity and hepatic lipidosis can exacerbate the inflammatory response and worsen the clinical course.

Clinical signs of lymphocytic cholangitis are often insidious and may be intermittent. Common signs include anorexia, weight loss, vomiting, diarrhea, and lethargy. Polyuria and polydipsia may be present due to impaired liver function. Icterus is a prominent finding in many cats, particularly in advanced stages. Fever may be present, especially during acute flares. Hepatomegaly may be detected on abdominal palpation, though in chronic cases the liver may be small and firm. Ascites is uncommon but may occur with cirrhosis and portal hypertension. In some cats, the disease is an incidental finding on blood work or abdominal ultrasound performed for other reasons. The clinical course can be progressive, with episodes of worsening signs interspersed with periods of relative well-being. In severe cases, hepatic encephalopathy may develop, manifesting as behavioral changes, ptyalism, and seizures. Cats with concurrent inflammatory bowel disease may have more prominent gastrointestinal signs, while those with pancreatitis may present with abdominal pain and vomiting.

Differential diagnoses for lymphocytic cholangitis include: 1) Neutrophilic cholangitis (bacterial cholangitis), which is characterized by a predominantly neutrophilic infiltrate and often responds to antibiotics; 2) Hepatic lipidosis, which is associated with marked hepatocellular vacuolation and is often triggered by anorexia; 3) Cholangiohepatitis (mixed inflammatory infiltrate), which may represent a transitional stage; 4) Biliary obstruction due to cholelithiasis, neoplasia, or stricture, which can cause similar clinical signs and laboratory abnormalities; 5) Primary hepatobiliary neoplasia, such as lymphoma or adenocarcinoma, which may present with a mass lesion or diffuse infiltration; 6) Feline infectious peritonitis (FIP), which can cause granulomatous inflammation and pyogranulomatous lesions; 7) Toxoplasmosis, which may cause multifocal hepatic necrosis and inflammation; 8) Amyloidosis, which is rare in cats but can cause hepatomegaly and liver dysfunction; 9) Copper-associated hepatopathy, which is more common in dogs but can occur in cats; 10) Drug-induced hepatopathy, which may mimic inflammatory liver disease. Definitive diagnosis requires histopathology, as clinical signs and laboratory findings are often nonspecific.

The diagnostic algorithm for lymphocytic cholangitis begins with a thorough history and physical examination, with particular attention to body condition, hydration status, and abdominal palpation. Initial laboratory tests include a complete blood count, serum biochemistry profile, and urinalysis. If liver disease is suspected, a serum bile acids test (fasting and postprandial) is recommended. Abdominal ultrasound is a key imaging modality to assess liver size, echogenicity, and the biliary system, and to guide fine-needle aspiration or biopsy. If ultrasound findings are suggestive of cholangitis, a fine-needle aspirate of the liver may be performed for cytology, though histopathology is required for definitive diagnosis. A liver biopsy, obtained via ultrasound-guided needle biopsy, laparoscopic biopsy, or surgical wedge biopsy, is the gold standard. In cats with suspected triaditis, additional diagnostics include serum feline pancreatic lipase immunoreactivity (fPLI) and intestinal biopsies via endoscopy or laparotomy. Serology for infectious agents (e.g., Toxoplasma, Bartonella, FeLV, FIV) may be considered. If biliary obstruction is suspected, advanced imaging such as computed tomography (CT) or magnetic resonance cholangiopancreatography (MRCP) may be indicated. The diagnostic algorithm should be stepwise, with non-invasive tests first, followed by more invasive procedures as needed.

Laboratory findings in lymphocytic cholangitis typically include elevated liver enzymes, particularly alanine aminotransferase (ALT) and aspartate aminotransferase (AST), reflecting hepatocellular injury. Alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT) are often elevated due to cholestasis. Hyperbilirubinemia is common, with conjugated bilirubin predominating. Serum bile acids are typically elevated, both fasting and postprandial. Hematologic abnormalities may include a mild anemia, often non-regenerative, and a stress leukogram. In some cats, eosinophilia may be present. Serum protein electrophoresis may show hyperglobulinemia, particularly beta and gamma globulins, due to chronic inflammation. Coagulation times (PT, aPTT) may be prolonged in advanced liver disease due to decreased synthesis of clotting factors. Urinalysis may reveal bilirubinuria, which is abnormal in cats. Serum fPLI may be elevated if concurrent pancreatitis is present. In cats with triaditis, serum cobalamin (vitamin B12) levels may be low due to intestinal disease. In advanced cirrhosis, hypoalbuminemia, hypoglycemia, and elevated blood ammonia may be observed. Specific biomarkers such as serum amyloid A (SAA) may be elevated as an acute phase protein.

Abdominal radiography may show hepatomegaly, though it is often unremarkable in early disease. In chronic cases, the liver may be small and irregular. Abdominal ultrasound is the most useful imaging modality. Findings may include a diffusely hyperechoic liver with a coarse echotexture, increased echogenicity of the portal triads, and thickening of the gallbladder wall. The bile ducts may be dilated, and the gallbladder may contain sludge or choleliths. In some cases, a distinct mass lesion may be seen, which could represent a focal inflammatory nodule or neoplasia. Doppler ultrasound can assess hepatic blood flow and portal hypertension. Computed tomography (CT) may provide more detailed evaluation of the liver and biliary tree, particularly if neoplasia or obstruction is suspected. Magnetic resonance imaging (MRI) with cholangiopancreatography (MRCP) is excellent for evaluating the biliary system and can identify strictures or obstructions. Endoscopic retrograde cholangiopancreatography (ERCP) is rarely performed in cats but may be used for therapeutic intervention. In cases of suspected triaditis, abdominal ultrasound may also reveal thickening of the intestinal wall and pancreatic changes.

Cytology from fine-needle aspiration of the liver may show a mixed population of lymphocytes and plasma cells, but it is often nondiagnostic and cannot reliably distinguish lymphocytic cholangitis from other inflammatory or neoplastic conditions. Histopathology is the gold standard. On biopsy, the characteristic finding is a dense infiltration of the portal tracts with small lymphocytes, often with fewer plasma cells and macrophages. The inflammatory infiltrate surrounds and may infiltrate the bile ducts, causing bile duct injury and proliferation. In early stages, the hepatic architecture is preserved, but as the disease progresses, there is bridging fibrosis, piecemeal necrosis, and eventually cirrhosis. Special stains, such as Masson's trichrome for fibrosis and cytokeratin stains for bile ducts, may be helpful. In some cases, the inflammation may be predominantly periportal, while in others it may be diffuse. The presence of concurrent inflammatory bowel disease or pancreatitis should be noted. Histopathology is essential to rule out other causes of hepatitis, such as lymphoma, which may have a similar clinical presentation but requires different treatment.

Treatment of lymphocytic cholangitis is aimed at suppressing the immune response, managing cholestasis, and providing supportive care. The mainstay of therapy is immunosuppression with glucocorticoids, such as prednisolone, at an initial dose of 2-4 mg/kg/day PO, tapering over several weeks to the lowest effective dose. In cats that do not respond to glucocorticoids alone, additional immunosuppressive agents such as chlorambucil (0.1-0.2 mg/kg q48h PO) or cyclosporine (5 mg/kg q24h PO) may be added. Ursodeoxycholic acid (UDCA) is a bile acid that has immunomodulatory and cytoprotective effects and is commonly used at a dose of 10-15 mg/kg/day PO. Antibiotics are not routinely indicated unless there is evidence of bacterial infection, but in cases of suspected secondary bacterial cholangitis, a course of amoxicillin-clavulanate (12.5-25 mg/kg q12h PO) or metronidazole (10 mg/kg q12h PO) may be considered. Supportive care includes fluid therapy with balanced electrolyte solutions, antiemetics such as maropitant (1 mg/kg q24h SC or PO) or ondansetron (0.5-1 mg/kg q12h IV or PO), and appetite stimulants such as mirtazapine (1.88 mg/cat q48h PO) or cyproheptadine (2-4 mg/cat q12h PO). Nutritional support is crucial, and a high-quality, highly digestible diet is recommended. In cats with hepatic encephalopathy, protein restriction and lactulose (0.5-1 mL/kg q8h PO) may be necessary. In severe cases, hospitalization with intensive care may be required. Surgical intervention is rarely needed, but may be considered for biliary obstruction or for biopsy.

The prognosis for lymphocytic cholangitis is variable and depends on the severity of disease at diagnosis and response to therapy. With appropriate immunosuppressive treatment, many cats show clinical improvement within 2-4 weeks, and long-term remission is possible. However, the disease is often progressive, and some cats may require lifelong therapy. The presence of concurrent triaditis, particularly with severe pancreatitis, is associated with a poorer prognosis. Advanced fibrosis or cirrhosis at diagnosis is a negative prognostic indicator, as is the development of complications such as hepatic encephalopathy, ascites, or portal hypertension. Cats that respond well to initial therapy and maintain stable liver function have a median survival time of 1-3 years, though some may live longer. In one study, cats with lymphocytic cholangitis had a median survival of 1.5 years, with a 1-year survival rate of 70%. Early diagnosis and aggressive treatment may improve outcomes. Regular monitoring of liver enzymes and clinical signs is essential to adjust therapy and detect relapse.

Follow-up for cats with lymphocytic cholangitis should be structured and regular. Initially, re-evaluation is recommended every 2-4 weeks until clinical signs are controlled and liver enzymes are improving. At each visit, a physical examination, body weight, and serum biochemistry profile (including liver enzymes, bilirubin, and bile acids) should be performed. Once stable, re-checks can be extended to every 3-6 months. Serial abdominal ultrasound may be performed every 6-12 months to assess liver architecture and detect progression of fibrosis or the development of neoplasia. If the cat is on immunosuppressive therapy, complete blood counts should be monitored regularly to detect bone marrow suppression, particularly with chlorambucil or cyclosporine. Drug dosages should be tapered gradually, and any relapse in clinical signs or laboratory abnormalities should prompt a re-evaluation and possible adjustment of therapy. Long-term management includes dietary recommendations, such as a balanced, highly digestible diet, and possibly supplementation with cobalamin if deficient. Owners should be educated about the chronic nature of the disease and the importance of compliance with medication and follow-up appointments.

Pearls: 1) Always consider triaditis in cats with chronic vomiting, diarrhea, and elevated liver enzymes; measure fPLI and consider intestinal biopsies. 2) Histopathology is essential for diagnosis; a liver biopsy should be obtained early in the course of disease to guide therapy. 3) Ursodeoxycholic acid is a valuable adjunctive therapy that may help reduce cholestasis and inflammation. 4) In cats that do not respond to prednisolone alone, add chlorambucil rather than increasing the glucocorticoid dose to avoid steroid side effects. 5) Monitor cobalamin levels in cats with concurrent gastrointestinal signs, as deficiency is common and may require supplementation. Pitfalls: 1) Do not rely on cytology alone; it may miss the diagnosis and lead to inappropriate treatment. 2) Avoid using antibiotics without evidence of bacterial infection, as they may promote resistance and do not address the underlying immune-mediated process. 3) Do not taper immunosuppressive therapy too quickly, as this may lead to relapse. 4) Be cautious with the use of non-steroidal anti-inflammatory drugs, as they can worsen liver disease. 5) Do not overlook the possibility of hepatic lipidosis in anorexic cats, as it may complicate the clinical picture and require aggressive nutritional support.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are recommended for lymphocytic cholangitis in cats: 1) Prednisolone: 2-4 mg/kg/day PO initially, tapering to 0.5-1 mg/kg every other day over 4-6 weeks. Monitor for polyuria, polydipsia, and weight gain. 2) Chlorambucil: 0.1-0.2 mg/kg q48h PO, or 2 mg/cat q48h. Monitor CBC for neutropenia and thrombocytopenia. 3) Cyclosporine: 5 mg/kg q24h PO, with therapeutic drug monitoring to maintain trough levels of 250-500 ng/mL. 4) Ursodeoxycholic acid: 10-15 mg/kg/day PO, divided q12h or q24h. 5) Amoxicillin-clavulanate: 12.5-25 mg/kg q12h PO, if bacterial infection is suspected. 6) Metronidazole: 10 mg/kg q12h PO, for its immunomodulatory and anti-anaerobic effects. 7) Maropitant: 1 mg/kg q24h SC or PO, for antiemesis. 8) Ondansetron: 0.5-1 mg/kg q12h IV or PO, for refractory vomiting. 9) Mirtazapine: 1.88 mg/cat q48h PO, as an appetite stimulant. 10) Cyproheptadine: 2-4 mg/cat q12h PO, as an alternative appetite stimulant. 11) Lactulose: 0.5-1 mL/kg q8h PO, for hepatic encephalopathy. 12) Cobalamin: 250-500 μg/cat SC weekly for 6 weeks, then monthly, if deficient. All dosages should be adjusted based on renal and hepatic function, and drug interactions should be considered, particularly with cyclosporine and other CYP450 inhibitors.

Evidence-based literature on lymphocytic cholangitis is limited, but several key studies and consensus statements provide guidance. A landmark study by Gagne et al. (1996) described the clinical and histopathologic features of lymphocytic cholangitis in cats, establishing it as a distinct entity. A more recent study by Otte et al. (2017) evaluated the association between inflammatory bowel disease and cholangitis, supporting the concept of triaditis. The ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in cats (2019) recommends histopathology for definitive diagnosis and immunosuppressive therapy with glucocorticoids and adjunctive agents. A study by Center et al. (2013) demonstrated the efficacy of ursodeoxycholic acid in improving liver enzymes and clinical signs in cats with cholangitis. Regarding treatment, a retrospective study by Marolf et al. (2012) found that cats treated with prednisolone and chlorambucil had a longer survival time compared to those treated with prednisolone alone. Another study by Callahan Clark et al. (2012) reported that cats with triaditis had a poorer prognosis than those with cholangitis alone. There is a lack of randomized controlled trials, and most recommendations are based on expert opinion and retrospective studies. Future research should focus on prospective trials to evaluate optimal immunosuppressive protocols and the role of the microbiome in disease pathogenesis.